RTQ-PCR investigation in several primary breast cancer cohorts found that high ZNF217 mRNA levels were associated with shorter relapse-free survival (RFS) (univariate analysis, p = 0.003, p = 0.017 and p = 0.02 [20]; p = 0.015 [51]) and with the development of metastases (p = 0.002, p = 0.0008 and p = 0.025 [20]). This evidence concerns the gene ZNF217 and breast cancer.